Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | GAA | P10253 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.37 |
| ▸ | GRM5 | P41594 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5750764 | 0.89 | — | — | |
| SCHEMBL4087192 | 0.80 | — | — | |
| SCHEMBL17326877 | 0.73 | ALDH1A1 (0.37) | ALDH1A1GAAMAPTHSD17B10 | |
| SCHEMBL871100 | 0.69 | ITGB2 (0.38) | ALDH1A1GAAMAPTHSD17B10GRM5 | |
| SCHEMBL18229966 | 0.68 | ALDH1A1 (0.33) | ALDH1A1GAAMAPTHSD17B10 | |
| SCHEMBL8942627 | 0.67 | GAA (0.55) | ALDH1A1GAAMAPTHSD17B10GRM5 | |
| SCHEMBL56313 | 0.67 | GAA (0.55) | ALDH1A1GAAMAPTHSD17B10GRM5 | |
| SCHEMBL88894 | 0.67 | GAA (0.55) | ALDH1A1GAAMAPTHSD17B10GRM5 | |
| SCHEMBL871099 | 0.67 | GAA (0.55) | ALDH1A1GAAMAPTHSD17B10GRM5 | |
| SCHEMBL21462 | 0.67 | ITGB2 (0.50) | GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 720 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2020243459-A1 | THIADIAZOLYL DERIVATIVES AS DNA POLYMERASE THETA INHIBITORS | IDEAYA BIOSCIENCES, INC. (US) | 2020-12-03 | — | — | WO | claimed |
| US-20160031863-A1 | HISTONE DEACETYLASE INHIBITORS AND COMPOSITIONS AND METHODS OF USE THEREOF | BIOFOCUS DPI LIMITED (GB) | 2016-02-04 | — | — | US | claimed |
| WO-2014159214-A1 | HISTONE DEACETYLASE INHIBITORS AND COMPOSITIONS AND METHODS OF USE THEREOF | CHDI FOUNDATION, INC. (US) | 2014-10-02 | — | — | WO | claimed |
| US-20120220611-A1 | 1,3-BENZOXAZOLYL DERIVATIVES AS KINASE INHIBITORS | MERCK PATENT GMBH (DE) | 2012-08-30 | — | — | US | claimed |
| US-7994336-B2 | Azetidine compounds as orexin receptor antagonists | ACTELION PHARMACEUTICALS LTD. (CH) | 2011-08-09 | — | — | US | claimed |
| EP-2069332-B1 | AZETIDINE COMPOUNDS AS OREXIN RECEPTOR ANTAGONISTS | ACTELION PHARMACEUTICALS LTD (CH) | 2011-03-02 | — | — | EP | claimed |
| US-20100222600-A1 | AZETIDINE COMPOUNDS AS OREXIN RECEPTOR ANTAGONISTS | ACTELION PHARMACEUTICALS LTD. (CH) | 2010-09-02 | — | — | US | claimed |
| EP-2146720-A1 | ARYLOXY-AND HETEROARYLOXY-SUBSTITUTED TETRAHYDROBENZAZEPINES AND USE THEREOF TO BLOCK REUPTAKE OF NOREPINEPHRINE, DOPAMINE, AND SEROTONIN | AMR Technology, Inc. (US) | 2010-01-27 | — | — | EP | claimed |
| EP-2146722-A1 | ARYL- AND HETEROARYL-SUBSTITUTED TETRAHYDROBENZO-1,4-DIAZEPINES AND USE THEREOF TO BLOCK REUPTAKE OF NOREPINEPHRINE, DOPAMINE, AND SEROTONIN | AMR Technology, Inc. (US) | 2010-01-27 | — | — | EP | claimed |
| EP-2069332-A2 | AZETIDINE COMPOUNDS AS OREXIN RECEPTOR ANTAGONISTS | Actelion Pharmaceuticals Ltd. (CH) | 2009-06-17 | — | — | EP | claimed |
| US-7528139-B2 | Antitumor agents; N-[4-(4-amino-5-oxo-5H-pyrido[2,3-d]pyrimidin-8-yl)phenyl]-2,3-dichlorobenzenesulfonamide; inhibitors of tyrosine kinases, in particular TIE-2, and Raf kinases; sulfonamidation | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 2009-05-05 | — | — | US | claimed |
| WO-2008141081-A1 | ARYL- AND HETEROARYL-SUBSTITUTED TETRAHYDROBENZO-1,4-DIAZEPINES AND USE THEREOF TO BLOCK REUPTAKE OF NOREPINEPHRINE, DOPAMINE, AND SEROTONIN | AMR TECHNOLOGY, INC. (US) | 2008-11-20 | — | — | WO | claimed |
| WO-2008141082-A1 | ARYLOXY-AND HETEROARYLOXY-SUBSTITUTED TETRAHYDROBENZAZEPINES AND USE THEREOF TO BLOCK REUPTAKE OF NOREPINEPHRINE, DOPAMINE, AND SEROTONIN | AMR TECHNOLOGY, INC. (US) | 2008-11-20 | — | — | WO | claimed |
| WO-2008020405-A2 | AZETIDINE COMPOUNDS AS OREXIN RECEPTOR ANTAGONISTS | ACTELION PHARMACEUTICALS LTD (CH) | 2008-02-21 | — | — | WO | claimed |
| US-12016852-B2 | Pyrrolidine glycosidase inhibitors | ASCENEURON SA (CH) | 2024-06-25 | — | — | US | disclosed |
| EP-4352055-A1 | O-LINKED THIADIAZOLYL COMPOUNDS AS DNA POLYMERASE THETA INHIBITORS | Ideaya Biosciences, Inc. (US) | 2024-04-17 | — | — | EP | disclosed |
| US-20240083829-A1 | PROCESS FOR THE ASYMMETRIC SYNTHESIS OF ISOPIPERITENOL | STUDIENGESELLSCHAFT KOHLE GGMBH (DE) | 2024-03-14 | — | — | US | disclosed |
| US-20030166694-A1 | Glycinamides | MERCK PATENT GMBH (DE) | 2003-09-04 | — | — | US | disclosed |
| WO-2002070471-A1 | PHENYL DERIVATIVES AND THEIR USE IN THE TREATMENT OF THROMBOEMBOLIC DISORDERS OR TUMOURS | MERCK PATENT GMBH (DE) | 2002-09-12 | — | — | WO | disclosed |
| WO-2002057236-A1 | PHENYL DERIVATIVES | MERCK PATENT GMBH (DE) | 2002-07-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240083829-A1 | PROCESS FOR THE ASYMMETRIC SYNTHESIS OF ISOPIPERITENOL | COASY, DHPS, GGPS1 | ALDH1A1 2051/4885GAA 2942/4885MAPT 3202/4885 |
| US-12016852-B2 | Pyrrolidine glycosidase inhibitors | PREP, GAA, DNPEP | ALDH1A1 1182/4885GAA 2/4885MAPT 22/4885 |
| US-20100222600-A1 | AZETIDINE COMPOUNDS AS OREXIN RECEPTOR ANTAGONISTS | HCRTR2, HCRTR1, NPY1R | ALDH1A1 1961/4885GAA 2145/4885MAPT 2439/4885 |
| US-20120220611-A1 | 1,3-BENZOXAZOLYL DERIVATIVES AS KINASE INHIBITORS | TIE1, FLT1, KDR | ALDH1A1 702/4885GAA 2438/4885MAPT 2449/4885 |
| US-20030166694-A1 | Glycinamides | F11, SERPINC1, F13A1 | ALDH1A1 540/4885GAA 591/4885MAPT 4813/4885 |
| US-20160031863-A1 | HISTONE DEACETYLASE INHIBITORS AND COMPOSITIONS AND METHODS OF USE THEREOF | HDAC1, HDAC7, HDAC5 | ALDH1A1 559/4885GAA 100/4885MAPT 3029/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.